Promacta(eltrombopag) once daily use drug for use in patients with Sever Aplastic Anaemia(SAA) who do not respond sufficiently to Imuunosuprresvie therpay(IST) is developed by GSK and gets sNDA approval from United States Food and Drug Administration(US FDA) .Earlier Promacta gained breakthrough therapy desigantion status in January '14.
Sever aplastic Anaemia is a serious blood disorder where the bone marrow fails to generate enough new Red and White Blood cells and Platelets. 300 to600 new SAA cases are reported every year in United States of America (USA)
Eltrombopag is a small molecule agonist of the c-mpl (TpoR) receptor, which is the physiological target of the hormone thrombopoietin